This article was automatically generated by Dow Jones using technology from Automated Insights.
Shares of Incyte Corp. shed 3.2% to $60.00 on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index falling 1.1% to 5,614.66 and Dow Jones Industrial Average falling 0.6% to 41,581.31.
This was the stock's second consecutive day of losses.
Incyte Corp. closed 28.5% short of its 52-week high of $83.95, which the company reached on November 8th.
The stock demonstrated a mixed performance when compared to some of its competitors, as Alnylam Pharmaceuticals Inc. fell 3.5% to $244.30, Bio-Techne Corp. rose 0.4% to $62.83, and BioMarin Pharmaceutical Inc. remained unchanged.
Trading volume totaled 3.3 million, compared to the 50-day average of 1.7 million.
Data source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
March 18, 2025 16:35 ET (20:35 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。